HMGCR和罗斯瓦斯塔丁调节GLP-1的分泌和表达 - 一项翻译性研究
Michael G Miskelly1, Andreas Lindqvist1, Amra Jujić2
1Neuroendocrine Cell Biology, Lund University, Malmö, Sweden.
The Journal of clinical endocrinology and metabolism
|November 8, 2025
概括
像罗斯瓦斯塔丁这样的他类药物可能通过影响类似葡萄糖-1 (GLP-1) 的分泌而影响血糖. 这项研究发现,HMGCR抑制降低了GLP-1,这可能解释了他类药物诱导的高血糖症.
科学领域:
- 内分泌学 在内分泌学.
- 代谢性疾病研究研究.
- 药理学 药理学是指药理学的学科.
背景情况:
- 立方体使用与2型糖尿病风险增加和轻度高血糖症有关.
- 与他类药物相关的葡萄糖不耐症背后的机制尚未完全理解.
- 对于他类药物对类似葡萄糖-1 (GLP-1) 的分泌的影响尚不清楚.
研究的目的:
- 研究罗斯瓦斯塔丁对GLP-1分泌和产生的影响.
- 探索HMGCR在规范GLP-1中的作用.
主要方法:
- 在马尔默饮食和癌症研究中进行的人类协会研究.
- 使用GLUTag细胞进行体外实验.
- 在C57Bl/6j小鼠中进行了急性和慢性研究.
主要成果:
- 在非糖尿病患者中,他类药物的使用与更高的GIP,胰岛素,葡萄糖,葡萄糖和HOMA-IR相关,但不是GLP-1.
- 在2型糖尿病患者中,他类药物的使用与更高的禁食GLP-1有关.
- 罗斯瓦斯塔丁和HMGCR knockdown降低了GLP-1分泌量,并在GLUTag细胞中增加了GCg mRNA.
- 急性罗斯瓦斯塔丁降低了食后GLP-1;慢性治疗小鼠导致高血糖症和食后GLP-1增加.
- HMGCR抑制对GLP-1的影响被PCSK9抑制剂模仿,这表明一种取决于胆固醇的途径.
结论:
- HMGCR被认为是GLP-1分泌的调节剂.
- 这提供了与他类药物相关的轻度高血糖症的潜在机制.
- 在处方罗斯瓦斯塔丁时建议监测血糖,因为它对GLP-1分泌有严重的负面影响.
相关概念视频
Glucagon-like Receptor Agonists
828
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
828
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.3K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
Oral Hypoglycemic Agents: Glinides
577
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
577
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
511
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
511
Dipeptidyl Peptidase 4 Inhibitors
570
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
570
Hormones Regulating Blood Glucose
6.4K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
6.4K


